Business
Change of Registered Address
Thalia Therapeutics plc has announced an immediate change to its registered address to 2 Portman Street, London, W1H 6DU. The company, which is developing its proprietary gene delivery system Nuvec® for advanced therapies, made this announcement on April 20, 2026. This administrative update is the sole focus of the RNS release and does not contain any financial performance data or strategic operational changes that would directly impact the stock share price. Disclaimer*
About this update from Thalia Therapeutics Plc
20 April 2026 Thalia Therapeutics plc ("Thalia" or the "Company") Change of Registered Address Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it has changed its registered address to 2 Portman Street, London, W1H 6DU with immediate effect. - Ends - For more information please contact: Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer Via Thalia Investor Hub https://investors.thaliatx.com/link/y5RKGe SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44 (0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall Tel: +44 (0)20 3657 0050 Northstar Communications Limited Investor Relations Sarah Hollins Tel: +44 (0)20 7183 2463 About Thalia Therapeutics plc Thalia Therapeutics plc is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare. RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets. Nuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to enable oral delivery, avoidance of unwanted immune responses, and excellent stability and storage. For further information visit www.thaliatx.com
View stock analysis, news, and events for Thalia Therapeutics Plc